Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases

• DOI: 10.1007/s00246-017-1688-4
• Publication Date: 2017-08-05T01:55:41Z
• Authors: Jeng-Sheng Chang; Ping-Yun Chiou; Shu-Hui Yao; I-Ching Chou; Ching-Yuang Lin
• Keywords: Rhabdomyoma; Everolimus; Vascular surgery

Cardiac rhabdomyoma (CR) is the most common cardiac tumor in newborns. Approximately 75% of cases are associated with tuberous sclerosis complex. Although these tumors usually spontaneously regress after 2 years age, they can be life-threatening when obstruct major inflow or outflow pathways. Everolimus an inhibitor mammalian target rapamycin, reducing its production proteins harmartin and tuberin. has demonstrated a remarkable suppression effect children complex at doses 4.7–5.6 mg/M2/day serum trough levels 5–15 ng/mL. Since 2012, five case reports neonates CR have also reported tumor-regressing everolimus. However, optimal dosage for still unknown. Over past years, we deliberately used low dose everolimus regimen (0.3–0.67 mg/M2/day) three large CRs, effort to maintain 3–7 In all cases, regressed smoothly within months. Regarding drug's side predisposing patients infection, observed that adenovirus pneumonia occurred one 3 months chicken pox another 9 age; both recovered smoothly. Our neonatal demonstrate low-dose effective treatment regression.